1. Home
  2. ATEN vs AUPH Comparison

ATEN vs AUPH Comparison

Compare ATEN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$30.09

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.05

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEN
AUPH
Founded
2004
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
ATEN
AUPH
Price
$30.09
$15.05
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
$26.33
$17.25
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
0.90%
N/A
EPS Growth
N/A
5075.00
EPS
0.17
0.25
Revenue
$235,429,000.00
$283,055,000.00
Revenue This Year
$13.02
$17.54
Revenue Next Year
$10.82
$15.74
P/E Ratio
$169.29
$60.72
Revenue Growth
2.36
20.38
52 Week Low
$16.52
$9.35
52 Week High
$38.49
$19.25

Technical Indicators

Market Signals
Indicator
ATEN
AUPH
Relative Strength Index (RSI) 26.35 42.19
Support Level $17.00 $14.60
Resistance Level $32.95 $15.23
Average True Range (ATR) 1.54 0.55
MACD -0.98 -0.09
Stochastic Oscillator 0.00 19.53

Price Performance

Historical Comparison
ATEN
AUPH

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: